Literature DB >> 9070712

Fertilization with human testicular spermatids: four successful pregnancies.

S Antinori1, C Versaci, G Dani, M Antinori, D Pozza, H A Selman.   

Abstract

Between July 1995 and May 1996, 36 patients with non-obstructive azoospermia of secretory origin underwent intracytoplasmic injection of spermatids. A previous histological biopsy was performed on all patients: 15 had spermatogenic arrest, a further 13 had Sertoli cell-only syndrome, and the remaining eight had post-cryptorchidism tubal atrophy. The ejaculate was duly examined and a complete absence of spermatozoa and spermatids was confirmed, with only bacteria and debris being found. Testicular sperm extraction (TESE) was then performed. In 19 out of 36 cases round spermatids only were found, while elongated spermatids were found in the remaining 17. Both round and elongated spermatids were isolated and used for injection. A total of 135 oocytes at metaphase II were recovered from 19 partners and injected with round spermatids, while 123 mature oocytes from 17 partners were injected with elongated spermatids. The number of oocytes fertilized, as judged by the presence of two pronuclei, was 75 (55.5%) and 71 (57.7%) respectively. By 34 h after injection, the number of embryos which had cleaved to the 2-cell stage was 56 (74.6%) with round spermatids and 55 (77.4%) with elongated spermatids. All cleaved embryos were transferred into the uterus of the partners. Clinical pregnancies were established in two cases of round spermatid cycles (10.5%) (both are still ongoing), and three cases of elongated spermatid cycles (17.6%) (two are still ongoing; one was lost after 8 weeks of gestation). Chromosomal analysis showed that all fetuses had a normal karyotype (three male and one female) with no chromosomal abnormalities.

Entities:  

Mesh:

Year:  1997        PMID: 9070712     DOI: 10.1093/humrep/12.2.286

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  8 in total

1.  Intracytoplasmic injection using spermatids and subsequent pregnancies: round versus elongated spermatids.

Authors:  Mohammad A Khalili; Abbas Aflatoonian; Panos M Zavos
Journal:  J Assist Reprod Genet       Date:  2002-02       Impact factor: 3.412

2.  Bypassing spermiogenesis for several generations does not have detrimental consequences on the fertility and neurobehavior of offspring: a study using the mouse.

Authors:  K L Tamashiro; Y Kimura; R J Blanchard; D C Blanchard; R Yanagimachi
Journal:  J Assist Reprod Genet       Date:  1999-07       Impact factor: 3.412

3.  Evaluation of parental mitochondrial inheritance in neonates born after intracytoplasmic sperm injection.

Authors:  C Danan; D Sternberg; A Van Steirteghem; C Cazeneuve; P Duquesnoy; C Besmond; M Goossens; W Lissens; S Amselem
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

4.  Development of blastocyst-stage embryos after round spermatid injection in patients with complete spermiogenesis failure.

Authors:  K Vicdan; A Z Isik; L Delilbaşi
Journal:  J Assist Reprod Genet       Date:  2001-02       Impact factor: 3.412

Review 5.  The present status of artificial oocyte activation in assisted reproductive technology.

Authors:  Kaoru Yanagida; Yoko Fujikura; Haruo Katayose
Journal:  Reprod Med Biol       Date:  2008-08-03

Review 6.  Intracytoplasmic spermatid injection and in vitro maturation: fact or fiction?

Authors:  Veerle Vloeberghs; Greta Verheyen; Herman Tournaye
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

Review 7.  Human iPS Cell-Derived Germ Cells: Current Status and Clinical Potential.

Authors:  Tetsuya Ishii
Journal:  J Clin Med       Date:  2014-10-13       Impact factor: 4.241

8.  Round spermatid injection into human oocytes: a systematic review and meta-analysis.

Authors:  Brent M Hanson; Taylor P Kohn; Alexander W Pastuszak; Richard T Scott; Philip J Cheng; James M Hotaling
Journal:  Asian J Androl       Date:  2021 Jul-Aug       Impact factor: 3.285

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.